Aurinia Pharmaceuticals (AUPH) Stock Statistics & Valuation Metrics

Aurinia Pharmaceuticals has a market cap or net worth of $1.59B. The enterprise value is $931.54M.

Aurinia Pharmaceuticals has 131,629,550 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aurinia Pharmaceuticals’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is -0.77%.

The current PE Ratio of Aurinia Pharmaceuticals is 28.3. Aurinia Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M and earned 5.75M in profits. Earnings per share was 0.04.

In the last 12 months, operating cash flow was 92.66M and capital expenditures -295.16K, giving a free cash flow of 92.38M billion.

Aurinia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Aurinia Pharmaceuticals upcoming earnings date is Oct 30, 2025, After Close (Confirmed).

Aurinia Pharmaceuticals as a current ratio of 4.57, with Debt / Equity ratio of 24.40%

In the past 12 months, Aurinia Pharmaceuticals has paid 1.70M in taxes.

Aurinia Pharmaceuticals EV to EBITDA ratio is 40.36, with an EV/FCF ratio of 29.03.

Aurinia Pharmaceuticals has $315.13M in cash and marketable securities with $81.83M in debt, giving a net cash position of -$233.30M billion.

Gross margin is 89.51%, with operating margin of -1.99%, and net profit margin of 2.45%.

The average price target for Aurinia Pharmaceuticals is $12.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy